相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes
S. van Dieren et al.
DIABETOLOGIA (2011)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes -: The PERISCOPE randomized controlled trial
Steven E. Nissen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes
Carine Beysen et al.
JOURNAL OF LIPID RESEARCH (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Jennifer G. Robinson
PPAR RESEARCH (2008)
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia
Mark A. Deeg et al.
DIABETES CARE (2007)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Philip Barter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus - A meta-analysis of randomized trials
A. Michael Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus:: Meta-analysis of randomized trials
Christoph Stettler et al.
AMERICAN HEART JOURNAL (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg et al.
DIABETES CARE (2005)
Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
E Selvin et al.
ANNALS OF INTERNAL MEDICINE (2004)
Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2 - A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins
AJ Taylor et al.
CIRCULATION (2004)
分享论文
